Our study proved that bleomycin can induce activation of TGF-β/Smad2/3 and WNT/β-catenin pathways in rat pulmonary fibrosis models, and GA may have dose-dependent antifibrotic effects through the TGF-β/Smad2/3 and WNT/β-catenin pathways, but the change cannot be completely reversed. The gene discussed is SMAD2; the disease is pulmonary fibrosis.